2nd Apr 2009 09:52
Tepnel Life Sciences plc ('Tepnel' or 'the Company')
Issue of Equity
Manchester, UK, 2 April 2009: Tepnel Life Sciences PLC (AIM: TED), the international Molecular Diagnostics and Research Products & Services group, today announces that the Board of Directors approved the issue of 1 new Ordinary Share of 1 pence to Gen-Probe Incorporated in connection with the Scheme of Arrangement, as detailed in the document sent to Shareholders on 21 February 2009.
Due to the timing of the issue it will not be possible to apply for the application of the 1 new Ordinary Share to be admitted to AIM. The number of shares in issue is as detailed in the Rule 2:10 announcement released today.
For further information:
Tepnel Life Sciences plc
Ben Matzilevich, CEO
Michael Slater, Group Finance Director
Carol Smith, Group Marketing Communications Manager
Tel: 0161 946 2200
Capital MS&L
Mary Clark or Catie Corcoran
Tel: +44 20 7307 5330
Seymour Pierce Limited
Mark Percy
Tom Sheldon
Christopher Wren
Tel: +44 20 7107 8000
About Tepnel Life Sciences plc
Tepnel Life Sciences (AIM:TED) is a UK-based international life sciences products and services Group with two divisions, Molecular Diagnostics and Research Products & Services. The Company has laboratories, manufacturing and operations in the USA, UK and France with over 200 employees. Tepnel provides test kits, reagents and services to two highly synergistic markets, these being Molecular Diagnostics and Biomedical Research. The Company's strategy has been to identify high growth niche opportunities within these multi-billion pound markets. Tepnel focuses on these niche operations with internally developed products, patents, expertise and know-how as well as strategic acquisitions, to develop a leadership position within these defined market segments. For more information please visit www.tepnel.com.
Related Shares:
TED.L